Immunogenicity Assessment: In Vitro Assays and Computational Analysis

ImmunXperts, a Q2 Solutions company, provides trusted immunogenicity risk assessment services, including in vitro methods with T-cell proliferation as surrogate to measure the immunogenic potential for drug candidates, in silico methods for rapid, low-cost assessment of large number of lead candidates, MHC-associated peptide proteomics (MAPPS), and anti-drug antibody (ADA) assays. ImmunXperts also performs functional screening assays for immuno-oncology candidates and risk assessment and mitigation of drug candidates’ immunogenicity profiles. ImmunXperts is a trusted leader in supporting immuno-oncology drug discovery.

In Silico

Computer-based tools for profiling and lead optimization allow fast, sequence-based, early-stage modeling to assess immunogenicity in large numbers of lead candidates. We use state-of-the-art, well-documented, and benchmarked immunological bioinformatics tools for algorithmic evaluation. These advanced tools, which are constantly being optimized by Prof. Morton Nielsen’s lab at the Technical University of Denmark, are ideal for:

  • T-cell epitope prediction
  • Immunogenicity risk assessment
  • Deimmunization
  • Customization

In Vitro

The in vitro immunogenicity services in our laboratory provide mechanistical and functional insights in immune-mediated adverse effects. Our assays include:

  • Peripheral Blood Mononuclear Cell (PBMC) assay
  • Dendritic Cell (DC-T) assay    
  • Human Lymphocyte Activation assay
  • Whole blood and PBMC cytokine release assay
  • MHC-associated Peptide Proteomics (MAPPS) assay
  • Dendritic Cell (DC) activation assay
  • Reporter cell line assays

Early Immunogenicity Assessment Tools

Immunogenicity Immuno-Functionality Inflammation / Auto-Immunity Immuno- Oncology Cell and Gene Therapy